The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 856-872

  Binder, Elisabeth B ^a   Kinkead, Becky ^b   Owens, Michael J ^b   Nemeroff, Charles B ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Neuropeptides; Neurotensin; Psychosis; Schizophrenia

Indexed keywords

1 (3 CHLORO 4 CYCLOHEXYLPHENYL) 3 (HEXAHYDRO 1 AZEPINYL)PROPENE; 2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 8 ETHYL 7,8 DIHYDRO 1,3,5 TRIMETHYL 1H IMIDAZO[1,2 C]PYRAZOLO[3,4 E]PYRIMIDINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; ETICLOPRIDE; FLUPENTIXOL; FLUPERLAPINE; HALOPERIDOL; LEVOCABASTINE; NEUROLEPTIC AGENT; NEUROTENSIN; OLANZAPINE; PIPOTIAZINE PALMITATE; PROTEIN G; QUETIAPINE; REMOXIPRIDE; RIMCAZOLE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; XENOPSIN;

BEHAVIOR; BIOCHEMISTRY; BRAIN REGION; CEREBROSPINAL FLUID; CLINICAL STUDY; CONFERENCE PAPER; DEPOLARIZATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN TARGETING; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; CLINICAL TRIALS; HUMANS; NEUROTENSIN; NEUROTRANSMITTER AGENTS; POLYMORPHISM, GENETIC; RECEPTORS, NEUROTENSIN; SCHIZOPHRENIA;

EID: 0035668473     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01211-2     Document Type: Conference Paper

References (158)

1. Neurotensin binding to dopamine
2. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice
3. EEDQ reduces the striatal neurotensin mRNA response to haloperidol
4. Neurotensin-induced excitation of neurons of the rat's frontal cortex studied intracellularly in vitro
5. Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: A detailed cellular co-expression study
6. Neuroleptics and striatal neuropeptide gene expression
7. Comparative sequencing of the proneurotensin gene and associated studies in schizophrenia
8. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems
9. The neuropathology of schizophrenia
10. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine
11. Cloning of human neurotensin/neuromedin N genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls
12. Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: An iontophoretic study
13. Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression
14. Involvement of neurotensin in latent inhibition
15. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating
16. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain
17. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra
18. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
19. CSF concentrations of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates
20. Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus
21. The current status of the dopamine hypothesis of schizophrenia
22. Schizophrenia
23. Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons
24. Molecular cloning of a levocabastine-sensitive neurotensin binding site
25. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy
26. Effects of haloperidol, quinelorane, and lithium on regional neurotensin/neuromedin N concentrations: Further evidence for neurotensin/neuromedin N-dopamine interactions
27. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
28. Dopamine in schizophrenia: A review and reconceptualization
29. Effect of muscimol on haloperidol-induced alteration of neurotensin gene expression in the striatum and nucleus accumbens in the rat
30. Utilization in psychiatric therapy of a centrally active phenothiazine
31. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens
32. Blunting of the neurotensin mRNA response to haloperidol in the striatum of aging rats: Possible relationship to decline in dopamine D2 receptor expression
33. Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action
34. Numbers of neurotensin-immunoreactive neurons selectively increased in rat ventral striatum following acute haloperidol administration
35. D1- and D2-dopamine occupancy during treatment with conventional and atypical neuroleptics
36. Further indication that distinct dopaminergic subsets project to the rat cerebral cortex: Lack of colocalization with neurotensin in the superficial dopaminergic fields of the anterior cingulate, motor, retrosplenial and visual cortices
37. The effects of intra-accumbens neurotensin on sensorimotor gating
38. Pro-dopamine effects of neurotensin on sensorimotor gating deficits
39. Elementary neuronal dysfunctions in schizophrenia
40. Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat
41. Neurotensin concentrations in rat striatum and nucleus accumbens: Further studies of their regulation
42. Receptor-receptor interactions and their relevance for receptor diversity: Focus on neuropeptide/dopamine interactions
43. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin
44. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients
45. Neurotensin innervation of the human cerebral cortex: Lack of colocalization with catecholamines
46. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia
47. DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs
48. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens
49. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
50. The modulation of corticoaccumbens transmission by limbic afferents and dopamine: A model for the pathophysiology of schizophrenia
51. Latent inhibition in drug naive schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPET
52. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor
53. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist
54. Differential effects of antipsychotic and psychotomimetic drugs on the neurotensin systems of discrete extrapyramidal and limbic regions
55. Comparison of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with clozapine and haloperidol
56. Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain
57. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems
58. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei
59. Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain
60. Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain
61. The effects of subchronic antipsychotic drug administration on neurotensin concentrations in the rat brain
62. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain
63. Normalization of information processing deficits in schizophrenia with clozapine
64. The sigma receptor ligand SR 31742A increases neurotensin in the nucleus accumbens but not in the caudate-putamen of the rat
65. Effects of the sigma receptor ligand SR 31742A on neurotensin biosynthesis in rat basal ganglia
66. [3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons: An autoradiographic study
67. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system
68. Characterization of the genomic structure, promoter region, and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene
69. Tetranucleotide repeat polymorphism in the human neurotensin receptor (NT-R) gene
70. Characterization of dopaminergic influence on striatal-nigral neurotensin systems
71. Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations
72. Effects of anticholinergic drugs on regional brain neurotensin concentrations
73. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs
74. BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum
75. Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate
76. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: Focus on haloperidol and BMY 14802
77. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: A receptor binding and microdialysis study
78. Antipsychotics and neuropeptides: The atypical profile of CI-943 and its relationship to neurotensin
79. Reduced CSF neurotensin concentration in drug-free schizophrenic patients
80. Latent inhibition: The effect of non reinforced pre-exposure to the conditioned stimulus
81. Human brain distribution of neurotensin in normals, schizophrenics, and Huntington's choreics
82. Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions
83. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain
84. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor
85. Disorders of attention and perception in early schizophrenia
86. C-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum
87. Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs
88. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions
89. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum
90. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics
91. Changes in the limbic neurotensin systems induced by dopaminergic drugs
92. Coexpression of neurotensin and c-fos mRNAs in rat neostriatal neurons following acute haloperidol
93. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain
94. Neurotensin induces an inward current in rat mesencephalic dopaminergic neurons
95. Risperidone does not elevate neurotensin mRNA in rat nucleus accumbens and caudate-putamen
96. Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes
97. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment
98. In vivo release of dopamine during perfusion of neurotensin in substantia nigra of the unrestrained rat
99. Neurotensin: Perchance an endogenous neuroleptic?
100. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome
101. Effects of the isomers of N-n-propylnorapomorphine and haloperidol on regional concentrations of neurotensin in rat brain
102. The effects of atypical antipsychotic drugs on regional brain neurotensin concentrations, NT and mRNA expression and extracellular fluid NT concentrations
103. Neuropeptides in Alzheimer's disease: A postmortem study
104. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia
105. Investigations about a direct neurotensin-dopamine interaction by nuclear magnetic resonance study, synaptosomal uptake of dopamine, and binding of neurotensin to its receptors
106. Pharmacological, molecular and functional characterization of glial neurotensin receptors
107. The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: An in vivo microdialysis study
108. Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia
109. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data
110. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography
111. The non-peptide neurotensin receptor antagonist SR48692 is not a potent antagonist of neurotensin(8-13) responses of rat substantia nigra neurones in vitro
112. The neurotensin analog xenopsin excites nigral dopamine neurons
113. Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat
114. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions
115. Peptides, the limbic lobe and schizophrenia
116. D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain
117. C-fos mediates antipsychotic-induced neurotensin gene expression in the rodent striatum
118. Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: Evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade
119. Chemical brain anatomy in schizophrenia
120. Subsets of neurotensin-immunoreactive neurons in the rat striatal complex following antagonism of the dopamine D2 receptor: An immunohistochemical double-labeling study using antibodies against Fos
121. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro
122. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder
123. Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons
124. Effects of neurotensin on midbrain dopamine neurons: Are they mediated by formation of a neurotensin-dopamine complex?
125. Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity
126. Actions of neurotensin: A review of the electrophysiological studies
127. Dopamine-mediated changes in central nervous system neurotensin systems: A role for NMDA receptors
128. Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: A combined in vivo electrochemical and electrophysiological study
129. Effects of neurotensin in a rodent model of tardive dyskinesia
130. Cross-species studies of sensorimotor gating of the startle reflex
131. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
132. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
133. Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function
134. Structure and functional expression of the cloned rat neurotensin receptor
135. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum
136. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens
137. Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum
138. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat
139. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra
140. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs
141. Psychphysiological aspects of schizophrenia
142. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor
143. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells
144. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene
145. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism
146. Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis
147. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration
148. Identification of a polymorphism in the human neurotensin receptor gene
149. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for a common ground
150. The switching model of latent inhibition: An update of neural substrates
151. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment
152. The effect of acute haloperidol treatment on brain proneurotensin mRNA: In situ hybridization analyses using a novel fluorescence detection procedure
153. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects
154. Subsets of neurotensin-immunoreactive neurons revealed following antagonism of the dopamine-mediated suppression of neurotensin immunoreactivity in the rat striatum
155. Distinct and interactive effects of d-amphetamine and haloperidol on levels of neurotensin and its mRNA in subterritories in the dorsal and ventral striatum of the rat
156. Temporal dissociation of neurotensin/neuromedin N mRNA expression in topographically separate subsets of rat striatal neurons following administration of haloperidol
157. Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: An immunohistochemical study
158. Solubilization and purification of a high affinity neurotensin receptor from newborn human brain